ADC Therapeutics SA Key Management Personnel Compensation Share-based Payment
ADC Therapeutics SA (ADCT) reported Key Management Personnel Compensation Share-based Payment of $1.82 million for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Notes › Compensation Related Costs
ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment · last filed 2023-11-07
- ADC Therapeutics SA key management personnel compensation share-based payment for the quarter ending 2023-09-30 was $1.82M, a 77.24% decline year-over-year.
- ADC Therapeutics SA key management personnel compensation share-based payment for the quarter ending 2023-06-30 was $3.07M, a 55.37% decline year-over-year.
- ADC Therapeutics SA key management personnel compensation share-based payment for the quarter ending 2023-03-31 was $3.64M, a 34.63% decline year-over-year.
- ADC Therapeutics SA key management personnel compensation share-based payment for the quarter ending 2022-12-31 was $2.86M, a 34.63% decline year-over-year.
| Period end | Key Management Personnel Compensation Share-based Payment 3 month | Key Management Personnel Compensation Share-based Payment 6 month | Key Management Personnel Compensation Share-based Payment 9 month | Key Management Personnel Compensation Share-based Payment 12 month |
|---|---|---|---|---|
| 2023-09-30 | $1.82M 6-K · filed 2023-11-07 | $4.89M derived: sum of 2 quarters · filed 2023-11-07 | $8.54M 6-K · filed 2023-11-07 | $11.40M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $3.07M 6-K · filed 2023-08-08 | $6.71M 6-K · filed 2023-08-08 | $9.57M derived: sum of 3 quarters · filed 2023-08-08 | $17.59M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $3.64M 6-K · filed 2023-05-09 | $6.51M derived: sum of 2 quarters · filed 2023-05-09 | $14.52M derived: sum of 3 quarters · filed 2023-11-07 | $21.39M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $2.86M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $10.87M derived: sum of 2 quarters · filed 2023-11-07 | $17.75M derived: sum of 3 quarters · filed 2023-11-07 | $23.32M 20-F · filed 2023-03-15 |
| 2022-09-30 | $8.01M 6-K · filed 2023-11-07 | $14.89M derived: sum of 2 quarters · filed 2023-11-07 | $20.46M 6-K · filed 2023-11-07 | $24.84M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $6.88M 6-K · filed 2023-08-08 | $12.45M 6-K · filed 2023-08-08 | $16.83M derived: sum of 3 quarters · filed 2023-08-08 | $23.28M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $5.57M 6-K · filed 2023-05-09 | $9.95M derived: sum of 2 quarters · filed 2023-05-09 | $16.40M derived: sum of 3 quarters · filed 2023-05-09 | $25.01M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $4.38M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $10.83M derived: sum of 2 quarters · filed 2023-03-15 | $19.43M derived: sum of 3 quarters · filed 2023-03-15 | $24.65M 20-F · filed 2023-03-15 |
| 2021-09-30 | $6.45M 6-K · filed 2022-11-08 | $15.05M derived: sum of 2 quarters · filed 2022-11-08 | $20.27M 6-K · filed 2022-11-08 | $25.77M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $8.60M 6-K · filed 2022-08-09 | $13.82M 6-K · filed 2022-08-09 | $19.33M derived: sum of 3 quarters · filed 2023-03-15 | $22.97M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $5.22M 6-K · filed 2022-05-09 | $10.72M derived: sum of 2 quarters · filed 2023-03-15 | $14.37M derived: sum of 3 quarters · filed 2023-03-15 | $20.39M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $5.50M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $9.15M derived: sum of 2 quarters · filed 2023-03-15 | $15.18M derived: sum of 3 quarters · filed 2023-03-15 | $16.75M 20-F · filed 2023-03-15 |
| 2020-09-30 | $3.65M 6-K · filed 2021-11-02 | $9.67M derived: sum of 2 quarters · filed 2021-11-02 | $11.25M 6-K · filed 2021-11-02 | |
| 2020-06-30 | $6.03M 6-K · filed 2021-08-03 | $7.60M 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $1.58M 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $396.00K 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $341.00K 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |